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The light chain of the major histocompatibility complex class 1 (MHC-1), the protein
2-microglobulin (2m), has amyloidogenic properties that arise only upon its dissociation
from the MHC-1. Here hydrogen/deuterium exchange electrospray ionization mass spectrom-
etry (HDX-ESI-MS) has been used to compare the solution dynamics of 2m in its MHC-1
bound state compared with those of 2m as a free monomer. The capability of tandem mass
spectrometry to dissociate the MHC-1 into its individual constituents in the gas phase
following deuterium incorporation in solution has permitted the direct observation of the
exchange properties of MHC-1 bound 2m for the first time. The HDX-ESI-MS data show
clearly that the H¡D exchange of MHC-1 bound 2m follows EX2 kinetics and that about 20
protons remain protected from exchange after 17 days. Free from the MHC-1, monomeric 2m
exhibits significantly different HDX behavior, which encompasses both EX1 and EX2 kinetics.
The EX2 kinetics indicate a tenfold increase in the rate of exchange compared with MHC-1
bound 2m, with just 10 protons remaining protected from EX2 exchange and therefore
exchanging only via the EX1 mechanism. The EX1 kinetics observed for unbound 2m are
consistent with unfolding of its exchange-protected core with a t1/2 of 68 min (pH 7, 37° C).
Thus, upon dissociation from the stabilizing influence of the MHC-1, free 2m becomes highly
dynamic and undergoes unfolding transitions that result in an aggregation-competent
protein. (J Am Soc Mass Spectrom 2009, 20, 278–286) © 2009 Published by Elsevier Inc. on
behalf of American Society for Mass SpectrometryThe major histocompatibility complex class 1(MHC-1), also known as the human leukocyteantigen (HLA), plays an important physiological
role in cellular immunity in the majority of vertebrates
[1]. MHC-1 molecules, which are expressed on the cell
surface, consist of a heavy  chain consisting of three
extracellular domains (1, 2, and 3), to which a light
chain, the protein 2-microglobulin (2m), is nonco-
valently bound [2, 3] (Figure 1). The MHC-1 molecules
(43.8 kDa) bind small (8- to 10-residue) peptides within
a peptide-binding groove that lies between the 1 and
2 domains of the heavy chain [4]. These peptides can
be derived from the organism itself or from foreign
species such as bacteria or viruses. The role of the
MHC-1 is in the differentiation of the origin of the
peptides to trigger an immune response against foreign
bodies [5–8].
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doi:10.1016/j.jasms.2008.10.005The light chain of the MHC-1 (2m) is a 99-residue
globular protein that has an immunoglobulin-like fold,
a single disulfide bridge, and, in recombinant form, an
additional N-terminal methionine residue giving a mo-
lecular mass of 11,860.4 Da (Figure 1) [9–11]. 2m is
released from the MHC-1 as part of its normal catabolic
cycle, whereupon it is degraded by the kidney. How-
ever, in renal insufficiency 2m is not degraded ade-
quately and the concentration of the protein in the
serum increases 25- to 60-fold, with the ultimate result
that the protein becomes deposited as insoluble fibrils
in the joints [9, 12]. Over the course of years this results
in the pathological condition dialysis-related amy-
loidosis and is characterized by considerable morbid-
ity resulting from joint destruction, pain, and loss of
mobility [13, 14].
The structural mechanism of amyloid fibril forma-
tion from unbound 2m, or indeed from other amyloi-
dogenic proteins, is unresolved and uncertainties re-
main regarding the identity of the aggregation nucleus
and how the fiber elongates, as well as the precise
structure of the final fibril itself [15–18]. The consensus,
however, is that for amyloid fibril formation to occur, at
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the protein from its native state is required [19, 20].
Therefore, an important question to address is: Are
there any conformational differences between 2m in its
nonamyloidogenic, MHC-1 bound state and 2m in its
assembly-competent, unbound state?
Here we use hydrogen/deuterium exchange moni-
tored by electrospray ionization mass spectrometry
(HDX-ESI-MS) [21] to investigate the possibility of
rarely populated, unfolded conformations of 2m, both
when the protein is in its monomeric state and also
when it is functioning as the noncovalently bound light
chain of the MHC-1 in the presence of a bound peptide.
The peptide used in these studies (LLFGYPVYV; 1069.6
Da) is a fragment from human T lymphotropic virus
type 1, the causative agent of T-cell leukemia, which is
known to bind to the MHC-1 in vivo [22, 23]. HDX-
ESI-MS is particularly well suited to uncovering un-
folded species within a native protein ensemble because
exchange arising from uncorrelated conformational
fluctuations (EX2) can be differentiated from exchange
arising from transient, large-scale unfolding events
(EX1) under appropriate conditions [24, 25]. Further-
more, the ability to use tandem mass spectrometry
(MS/MS) to dissociate the MHC-1 in the gas-phase
following deuterium incorporation in solution permits
the exchange properties of MHC-1 bound 2m to be
compared directly with those of unbound 2m, thus
revealing their differing conformational dynamics. Al-
though several publications can be found that discuss
the possibility of “hydrogen scrambling” in the gas
phase when using MS/MS collision-induced dissocia-
tion (CID) to fragment covalent bonds along the amide
backbone of a polypeptide (e.g., [26, 27]), previous
reports on HDX of noncovalently bound species fol-
lowed by in-source [28] or MS/MS-induced [29] disso-
Figure 1. Ribbon diagram of the MHC-1 (PDB 2VLL) [41] show-
ing the heavy chain (1, 2, 3; gray ribbon), the light chain (2m;
black ribbon), and a peptide (black stick) that binds in the cleft
formed by the two helical regions (1 and 2) of the heavy chain.
Drawn using PyMOL v.0.99 [42].ciation have indicated HDX levels of a subunit-specificmanner. Thus, in this study we demonstrate that the
conformational flexibility of MHC-1 bound 2m is sig-
nificantly restricted, whereas upon dissociation from
the stabilizing influence of the MHC-1 heavy chain, free
2m has increased conformational dynamics that result
in the transient population of potential aggregation-
competent conformers within the protein ensemble.
Experimental
Mutagenesis and Protein Purification
Protein purification of monomeric 2m were carried out
as described previously [20]. Preparation of the MHC-1
was carried out according to the published procedure
[30].
Reagents and Solvents
Reagents (ammonium acetate, ammonium formate,
deuterium oxide, Tris) and calibrants (horse heart myo-
globin and cesium iodide) were obtained from Sigma–
Aldrich (Dorset, UK). Solvents were purchased from
Fisher Scientific (Loughborough, UK).
H¡D Exchange of the MHC-1 Monitored by
ESI-MS and ESI-MS/MS
A stock solution of MHC-1 (150 M; 1:1:1 M ratio of
heavy chain, 2m, and peptide, confirmed by ESI-MS)
was stored at 80 °C in 10 mM ammonium formate:10
mM ammonium acetate at pH 7.0. This solution was
diluted 25-fold into 10 mM ammonium formate:10 mM
ammonium acetate in D2O [pH 7.0 (corrected) i.e.,
corrected for deuterium by subtracting 0.4 from the pH
reading: pD 7.4; 37 °C] to initiate H¡D exchange and
then incubated in a water bath (37 °C). Aliquots (70 L)
were removed at selected time points for analysis by
positive ESI-MS using a Synapt HDMS mass spectrom-
eter (Waters UK Ltd., Manchester, UK). The samples
were infused (20 L min1) with a syringe pump
(Harvard Apparatus, Holliston, MA, USA) and the
following instrument parameters were set: capillary
voltage 3.5 kV; sample cone 70 V; source temperature
60 °C; trap collision energy 6 V. Mass accuracy was
ensured by calibration with a separate introduction of
cesium iodide. Before each analysis, 100 L of buffer
was infused through the sample inlet system to saturate
the enclosed source with deuterium. For MS/MS CID
the leading edge of the most intense MHC-1 ions was
selected, followed by dissociation using a trap collision
energy of 80 V and argon collision gas. The centered5
and 6 charge state 2m monomer ions were used to
calculate the level of deuterium incorporation at each
time point. After about 17 days, degradation of the
sample rendered further analysis impractical.
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Lyophilized 2m was dissolved in 99.9% D2O (final
protein concentration 600 M) buffered to pH 8.0
(corrected) using 5 mM Tris and incubated at 37 °C for
24 h. Complete protein deuteration was confirmed by
positive ESI-MS at pH 7.0 (corrected) in 99.9% D2O,
buffered by 10 mM ammonium formate:10 mM ammo-
nium acetate, using a Platform II mass spectrometer
(Micromass UK Ltd., Manchester, UK). Samples were
infused (20 L min1) with a syringe pump (Harvard
Apparatus) and the following instrument parameters
were set: capillary voltage 3.5 kV; sample cone 40 V.
Mass accuracy was ensured by calibration with a sep-
arate introduction of horse heart myoglobin. A mass of
12,051.2 Da was measured for 2m (calculated fully
deuterated mass 12,051.6 Da). The protein solution was
sterilized by syringe filtration through a 0.2-mAnotop
10 filter (Whatman, Maidstone, UK) and the concentra-
tion determined by spectrophotometry at 280 nm (Ul-
trospec 2100 pro, Amersham Biosciences, Uppsala, Swe-
den) using an extinction coefficient of 20,065 M1 cm1
[31]. The solution was diluted to a final protein concen-
tration of 500 M, flash frozen, and stored at 20 °C.
D¡H Exchange of Monomeric Wild-Type 2m
Monitored by ESI-MS
The deuterated protein solution was thawed on ice and
diluted 25-fold into 10 mM ammonium formate:10 mM
ammonium acetate at pH 7.0, 37 °C to initiate D¡H
exchange. The solution was incubated in a water bath
(37 °C), from which 8-L aliquots were removed at
selected time points for analysis by positive
nanoESI-MS using either an LCT Premier (Waters UK
Ltd.) or a Synapt HDMS (Waters UK Ltd.) equipped
with a NanoMate (Advion Biosciences, Ithaca, NY,
USA) nanoESI interface and sample delivery system. A
capillary voltage of 1.8 kV and a nitrogen nebulizing
gas pressure of 0.8 psi were set, together with the
following instrument parameters for the LCT Premier:
sample cone 70 V; ion guide 1 70 V; aperture 1 10 V; ion
energy 100 V, or for the Synapt HDMS: sample cone 70
V; source temperature 60 °C; trap collision energy 6 V.
Mass accuracy was ensured by calibration with a sep-
arate introduction of horse heart myoglobin. This ex-
periment was performed several times on both the LCT
Premier and the Synapt HDMS, giving identical results
within experimental error (i.e., 67.6  3 min).
H¡D Exchange of Monomeric Wild-Type 2m
Monitored by ESI-MS
2m (500 M) in 5 mM Tris buffer was diluted 25-fold
into 99.9% D2O buffered to pH 7.0 (corrected) with 10
mM ammonium formate:10 mM ammonium acetate at
37 °C to initiate H¡D exchange. The solution was
incubated in a water bath (37 °C). Aliquots (30 L) were
removed at selected time points for analysis by positiveESI-MS using an LCT Premier (Waters UK Ltd.) mass
spectrometer. Samples were infused (20 L min1) with
a syringe pump (Harvard Apparatus) and the following
instrument parameters were set: capillary voltage 1.8
kV; sample cone 70 V; ion guide 1 70 V; aperture 1 10 V;
ion energy 100 V. Before each analysis, 100 L of buffer
was infused through the sample inlet system to saturate
the enclosed source with deuterium. The instrument
was calibrated with a separate introduction of horse
heart myoglobin.
Analysis of the Mass Spectrometry Data
The raw data were processed using MassLynx v.4.1
software (Waters UK Ltd.). The data were smoothed
(twice using the Savitsky–Golay algorithm) and cen-
tered (peak area).
To establish the contribution of the overlapping
sodium and potassium salt adducts of the EX1 peaks to
the EX2 peaks, each spectrum was fitted to two sets of
Gaussian curves centered on the EX1 and EX2 base
peaks using Igor Pro v.5.4 software (Wavemetrics Inc.,
Portland, OR, USA). For the nanoESI-MS analyses, the
base peaks were linked to three additional peaks: base
peak 28 Da, base peak 22 Da (Na), and base peak
38 Da (K). These peak positions were determined in
each spectrum by linking them and forcing them to
move with their respective base peak, whereas their
area in each spectrum was determined by their ratio
relative to the base peak, observed in the initial and
final spectra and assumed to be constant in their rela-
tive intensity to the base peak throughout exchange. For
ESI-MS analyses, each base peak was linked to two
additional adduct peaks; base peak 44 Da (2Na) and
base peak 60 Da (Na  K), which required addi-
tional Gaussian curves to adequately describe the data.
The accurate area and mass of each peak were deter-
mined using this method and these data were used to
plot the peak mass versus time course and also the areas
of the individual EX1 and EX2 peaks relative to the area
of the sum of the peaks versus time.
Results and Discussion
HDX-MS and HDX-MS/MS of Intact MHC-1
To characterize the behavior of the amyloidogenic pro-
tein 2m when in its bound state as the light chain of the
MHC-1, HDX was carried out on the intact, nonco-
valently bound MHC-1 by dilution of a protic solution
into a 25-fold volume excess of D2O at pH 7 (corrected),
37 °C. H¡D, rather than D¡H, exchange was chosen as
the more appropriate method for studying the intact
complex because of the inherent difficulty in fully
deuterating a highly protected, noncovalently bound
complex. The progress of HDX was monitored by
ESI-MS analysis of reaction mixture aliquots taken at
selected time points. Standard ESI-MS was used for the
H¡D continuous labeling experiments because the
281J Am Soc Mass Spectrom 2009, 20, 278–286 HDX-ESI-MS OF 2m UNBOUND AND MHC-1 BOUNDclosed nature of such atmospheric pressure ion sources
averts any D¡H back exchange during the ionization
process. Slightly higher flow rates than normal were
used to minimize exchange during the analysis (i.e.,
flow rates of 20 L min1 rather than 5–10 L min1).
Using the more open-style nanoESI (i.e., flow rates of
100 nL min1) source housing designs, back exchange
of the rapidly exchanging, labile protons was found to
occur during the ionization process.
The m/z spectrum of the MHC-1 (Figure 2a) shows
predominantly ions consistent with the intact MHC-1,
i.e., 12, 13, and 14 charge state ions at m/z 3729,
3442, and 3196, respectively (component C; measured
mass 44,738 Da), accompanied by trace amounts of the
free peptide (component A; MH, m/z 1071), the free
light chain (2m; component B; 6 and 7 charge
states, m/z 1978 and 1695, respectively; measured mass
11,860 Da), and the MHC-1 minus the peptide (compo-
nent D; 12 and 13 charge states, m/z 3640 and 3360,
respectively; measured mass 43,666 Da). To gain spe-
Figure 2. (a) ESI-MS m/z spectrum of the MHC-1 (pH 7.0),
showing predominantly intact MHC-1 (C), together with traces of
MHC-1 minus peptide (D), free 2m (B), and peptide (A). (b)
ESI-MS/MS m/z spectrum showing dissociation of intact MHC-1
(C; 13 charge state ions, m/z 3442) to yield: MHC-1 minus
peptide (D), MHC-1 heavy chain (E), free 2m (B), and peptide
(A). The number immediately following the letters A, B, C, D, and
E indicates the charge state of those ions.cific insights into the HDX properties of 2m exclu-
sively when in its bound state within the MHC-1,
MS/MS was used to dissociate the intact MHC-1 com-
plex into its individual components and thus present
the opportunity to monitor the HDX properties of each
protein component individually. Thus the most intense
MHC-1 ions, the 13 charge state ions (m/z 3442), were
selected and fragmented using argon collision gas. The
MS/MS spectrum (Figure 2b) indicates the presence of
residual trace amounts of the parent ions of the intact
MHC-1 (component C; 13 ions, m/z 3442), the MHC-1
minus the peptide (component D;12 charge state ions,
m/z 3640), the free heavy chain (component E; 7
charge state ions, m/z 4545), free 2m (component B; 5
and 6 charge state ions, m/z 2373 and 1978, respec-
tively), and the free peptide (component A; MH and
MNa ions, m/z 1071 and 1093, respectively). Because
all the species detected from the MS/MS analysis
originate directly from the intact MHC-1, we can be
sure that only HDX labeling of the complex, and not of
the minor components seen in the MS spectrum (Figure
2a), is being monitored using this methodology. Thus,
any unbound light chain or heavy chain molecules
existing in solution would not be m/z selected for
MS/MS in this experiment.
Focusing on the 5 charge state ions of 2m in the
MS/MS spectrum (m/z 2360–2440) enabled the extent of
deuterium labeling during the time course to be as-
sessed (Figure 3). From these data the reaction profile
could be formulated, showing the mass increase attrib-
uted to deuterium incorporation over time. From this
analysis, the exchange of MHC-1 bound 2m was found
to occur by EX2 kinetics with a rate of 0.002  0.0004
min1 and the theoretical end point of the exchange
(12,044 Da) was not reached even after 17 days (Figure
4). Because the analysis of fully deuterated 2m using
standard ESI-MS has shown that back exchange does
not occur during the ionization process—and thus
cannot be the reason for the incomplete deuteration
observed in this exchange reaction—these results indi-
cate a highly protected core of about 20 protons for
which stable hydrogen bonding and/or exclusion of
solvent precludes exchange under the conditions used.
HDX-MS of Unbound 2m
Having ascertained the HDX exchange profile of 2m
when bound within the MHC-1, the conformational
characteristics of this protein in its unbound, amyloid-
competent state were next investigated to compare the
dynamics of 2m in its MHC-1 bound and free states.
Previous studies have shown that unbound 2m retains
the native immunoglobulin fold of its bound counter-
part [10, 11, 32] and denatures apparently cooperatively
when subjected to urea titration [20]. Prior deuteration
of monomeric 2m (see Experimental section) allows
D¡H HDX-MS to be performed, whereas for undeu-
terated protein H¡D exchange can be monitored, the
two modes generating equivalent but complementary
ions (t  0) are shown in the inset.
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deuterated by dissolution in D2O at pH 8 (corrected; see
Experimental section) until ESI-MS analysis indicated
the maximum mass increase of 190 to 12,051.2 Da.
Dilution into a 25-fold volume excess of protonated
buffer was then carried out to initiate the exchange
reaction (pH 7, 37 °C). Within 2 min nanoESI-MS indi-
cated that 145 out of the possible 190 deuterons had
undergone exchange; the remaining 45 deuterons (i.e.,
those that are highly protected) exchanged more slowly,
presumably because they are involved in hydrogen bond-
ing in buried secondary structural elements. An advan-
tage of D¡H exchange is that nanoESI-MS can be used to
monitor the reaction because all of the extremely labile
deuterons exchange in solution within seconds,
whereas the slower-exchanging deuterons are unlikely
to exchange during the short time in the open, nanoESI
source. Further advantages of nanoESI-MS over ESI-MS
are that a lower degree of salt adduct ion formation is
observed and also less sample is consumed.
Figure 5 shows the nanoESI-MS m/z spectra high-
lighting the6 charge state ions of 2m (m/z 1940–2020)
from the first D¡H HDX time point over the following
10 h. A bimodal distribution of peaks is clearly ob-
served (black and gray peaks), as well as a gradual
decrease in mass of each peak over time, indicating that
exchange is occurring by mixed EX1 and EX2 kinetics.
The series of peaks at higher m/z (colored black in
Figure 5) indicates exchange by an EX2 mechanism
whereby deuterons are replaced gradually by protons
as a result of small, noncorrelated fluctuations that
expose deuterium atoms to solvent, consistent with the
conformational dynamics expected for a folded protein.
The appearance and subsequent increase in intensity of
the series of peaks at lower m/z (colored gray in Figure
5) are indicative of EX1 kinetics. Surprisingly for such a
Figure 4. The increase in molecular mass of 2m observed by
ESI-MS/MS dissociation of the intact MHC-1 over the course of
H¡D exchange (pH 7.0 corrected, 37 °C). A single-exponential fit
(gray line) indicates a rate constant of 0.002  0.0004 min1. The
theoretical end point of the reaction (12,044 Da; dashed line) isFigure 3. Time course showing H¡D exchange (pH 7.0 cor-
rected, 37 °C) of 2m, which has been dissociated from intact
MHC-1 after HDX by ESI-MS/MS. The 5 charge state ions are
highlighted showing m/z versus intensity over the time course.
The centroided m/z values of the ions are indicated on each
spectrum and the centroided m/z of the first time point is shown
throughout as a dashed line. The unexchanged 5 charge stateshown; about 20 protons remain protected.
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significant unfolding event involving the coordinated
exposure of deuterons to solvent. These peaks in-
crease in intensity during the exchange time course,
as more and more molecules visit an unfolded,
exchange-competent conformation in solution.
To determine the frequency with which the protein
molecules undergo the unfolding event that gives rise
to EX1 kinetics, and also the extent of that unfolding
event, the mass and intensity of the two series of peaks
require accurate evaluation. This presents a challenge
because the two series of peaks lie in close proximity on
the m/z scale, especially during the later time points of
the exchange reaction when the lower mass peaks
(representing molecules that have undergone EX1 ex-
change and referred to here as the EX1 peak) become
more intense and the low levels of sodium and potas-
sium adduct ions associated with these peaks overlap
with the higher mass peaks representing protonated/
deuterated molecules that have not undergone EX1
exchange (referred to here as the EX2 peak). An in-
house Gaussian-fitting procedure was developed that
circumvented this problem for the EX1-related peaks by
taking into account the relative intensities of the salt
adducts (see Experimental section). Thus, Figure 6a
shows the intensity of the EX1-related peak relative to
the sum of both EX1 and EX2 related peaks versus time,
from which t1/2 is estimated as 67.6  3 min.
To enable an accurate analysis of the rate of exchange
for the EX2 peak, the exchange was repeated in H¡D
mode, whereby the increase in mass during the ex-
change process avoids the interference of the sodium
and potassium adduct ions of the EX1 peak with the
now lower m/z EX2 peak. Standard ESI-MS was used in
this case to avoid back exchange during the ionization
process. The mass of the EX2 peak was thus measured
accurately throughout the time course (Figure 6b). The
EX2 rate of exchange from these data was calculated to
be 0.023  0.002 min1, some ten times faster than the
EX2 rate of HDX observed for 2m when bound as
the light chain of the MHC-1. The calculated mass of the
final, deuterated protein under these solution condi-
tions (i.e., 4% protonated solvent, 96% deuterated sol-
vent) is 12,043.6 Da (183 Da higher than the protonated
protein). In contrast, the measured mass of the EX2
peak reached a maximum of 12,033.8 Da at 100 min,
indicating a protected core of about 10 protons within
Figure 5. HDX-ESI-MS of unbound, monomeric 2m (pH 7,
37 °C) highlighting the 6 charge state ions showing m/z versus
intensity over the time course of the D¡H exchange reaction. The
black (higherm/z) peaks show the population of protein molecules
in solution that are undergoing exchange by an EX2 mechanism
alone, whereas the gray (lower m/z) peaks indicate the molecules
in solution that have experienced exchange by the EX1 mecha-
nism. The centroided m/z values of the ions are indicated on each
spectrum and the centroided m/z of the first time point is shown
throughout as a dashed line. The unexchanged 6 charge state
ions (t  0) are shown in the inset.
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via the EX1 mechanism. NMR studies undertaken under
these conditions identified nearly 25 slow-exchanging
residues located in the B, C, E, and F -sheet strands, i.e.,
clustered around the disulfide bridge connecting
strands B and F (data not shown), which is consistent
with published NMR data [33]. Among these approxi-
mately 25 residues are the 10 protons observed here to
exchange exclusively via an EX1 mechanism. Although
the NMR data provide residue-specific information,
they do not distinguish between EX1 and EX2 exchange
mechanisms. Thus the HDX-ESI-MS and HDX-NMR
data are completely complementary.
These HDX-ESI-MS data show clearly that when 2m
Figure 6. (a) The intensity of the EX1 peak relative to the total
protein signal during the D¡H exchange reaction monitored by
HDX-ESI-MS of unbound 2m (pH 7, 37 °C). The data fit to a
single exponential (gray line) with t1/2  67.6  3 min. (b) The
increase in mass of unbound 2m undergoing HDX by an EX2
mechanism observed by ESI-MS over the course of H¡D ex-
change (pH 7.0 corrected, 37 °C). A single-exponential fit (gray)
indicates a rate of 0.023  0.002 min1. The theoretical end point
of the reaction (12,044 Da; dashed line) is shown; about 10 protons
exchange only via an EX1 mechanism.is bound in the MHC-1, its H¡D exchange follows EX2kinetics with a rate of exchange of 0.002 0.0004 min1,
and indicates that approximately 20 protons are highly
protected from exchange. In comparison, when in an
unbound state free from the MHC-1, 2m exhibits very
different characteristics exemplified by HDX mecha-
nisms that encompass both EX1 and EX2 kinetics. The
EX2 kinetics show a tenfold increase in the rate of
exchange (0.023  0.002 min1) compared with MHC-1
bound 2m, and approximately 10 highly protected
protons exchange exclusively via an EX1 mechanism
rather than by combined EX1/EX2 kinetics. The EX1
data observed for unbound 2m are consistent with a
substantial cooperative unfolding event. Thus, binding
to the MHC-1 results in a significant damping of the
conformational dynamics of 2m, consistent with sta-
ble, macromolecular, protein complex architecture.
Conclusions
ESI-MS is a powerful technique with which to monitor
protein conformational dynamics using HDX. One of its
key features is the ability to follow multiple exchange
mechanisms simultaneously, as exemplified here by the
observation of concurrent EX1 and EX2 kinetics in the
case of unbound 2m. Thus, conformational changes
undergone by only a fraction of the protein molecules
can be observed and useful structural information
gained. Other, perhaps more evident, features are the
ability to monitor protein mass changes to within 0.01%
accuracy, thus giving precise information regarding the
extent of HDX having taken place, and also the capa-
bility of real-time reaction monitoring to generate im-
mediate results consuming only microliter volumes of
solutes. Furthermore, ESI-MS/MS permits surveillance
of the solution dynamics of individual components
within large noncovalently bound complexes, which is
an important and unique attribute of the technique.
Although HDX-MS of unbound 2m, as a mixture with
its oxidized C-terminal methionine analogue, has pre-
viously been shown to follow mixed EX1/EX2 mecha-
nisms [34, 35], here HDX-ESI-MS/MS has enabled a
direct comparison to be made for the first time between
the conformational dynamics of MHC-1 bound and free
2m. To detect MHC-1 bound 2m, the exclusive selec-
tion of MHC-1 ions by the first analyzer after HDX,
and the subsequent fragmentation of these ions to
release 2m for m/z analysis by the second analyzer,
ensured that only bound protein was examined in
these experiments.
The comparison between MHC-1 bound and un-
bound 2m highlights a remarkable change in the
conformational dynamics of 2m on its release from the
MHC-1. These observations are of significance, given
that partial or more complete unfolding is considered to
be the key initiating step in protein aggregation pro-
cesses that lead to disease-related fibril formation [19,
36, 37]. The binding interface between the light and
heavy chains of the MHC-1 has been probed by X-ray
crystallography, the data revealing a large (1348 Å2)
285J Am Soc Mass Spectrom 2009, 20, 278–286 HDX-ESI-MS OF 2m UNBOUND AND MHC-1 BOUNDinterface involving hydrogen bonding, salt bridges, and
hydrophobic interactions that stabilize the complex [3,
32, 38]. The larger number of protected residues within
2m when MHC-1 bound observed here is consistent
with these additional interactions and associated in-
crease in stability upon complex formation, as well as
with the reduction in the solvent accessible surface area
(30%) [32, 38].
The EX1 process observed for HDX of unbound 2m
does not lead directly to complete HDX of the protein,
in that further exchange is seen to occur following EX1
exchange via an EX2 mechanism. The options for this
phenomenon are either that it represents subglobal
unfolding or that the rate of the refolding event is such
that insufficient time is available for all labile protons to
undergo exchange [39]. Because there is evidence that
2m retains some residual structure even in the acid-
unfolded state at pH 2.5 [38, 40], some residual struc-
ture in the unfolded state at pH 7 may well be expected,
especially given the presence of the disulfide bond
(Cys25OCys80) connecting -strands B and F, which
remains intact in these experiments.
The stabilizing effect of the noncovalently bound
MHC-1 macromolecular structure on the conforma-
tional dynamics of 2m provides a clue for therapeutic
intervention against dialysis-related amyloidosis. Thus
binding of small molecules, aptamers, or antibodies
could be used to stabilize the native fold of 2m in a
similar manner and, consequently, prohibit the confor-
mational flexibility necessary to trigger amyloidosis.
The HDX-ESI-MS methods developed here represent an
efficient and practical assay to test the efficacy of such
inhibitors by monitoring their ability to affect the con-
formational dynamics of unbound, amyloidogenic 2m
relative to its MHC-1 bound counterpart.
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